sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the … effects of M&As on firms' post-merger R&D investments and drug development capabilities across drug development phases. This … study builds on a novel database that enables us to evaluate the post-merger effect at the research project level and across …

these structural changes contribute to the current merger wave, how dynamic responses by industry players in response to the … merger wave mitigate the potential harm from competition, and how the political arena might still offer threats to market …

differential merger outcomes are caused mostly by firms' technology or product market attributes. Furthermore, empirical merger …. We allow the merger responses to vary across firms, even after controlling for regressors, and apply a random …

The U.S. and EU Merger Guidelines strongly emphasize the relevance of the ease of entry argument in merger evaluations … related product markets. Finally, our results confirm that post-merger changes in the equilibrium number of firms directly …

differential merger outcomes are caused mostly by firms' technology or product market attributes. Furthermore, empirical merger …. We allow the merger responses to vary across firms, even after controlling for regressors, and apply a random …

The U.S. and EU Merger Guidelines strongly emphasize the relevance of the "ease of entry" argument in merger …

differential merger outcomes are caused mostly by firms' technology or product market attributes. Furthermore, empirical merger …. We allow the merger responses to vary across firms, even after controlling for regressors, and apply a random …